Oil prices surging past $90 per barrel for U.S. benchmark WTI crude and topping $100 for international standard Brent are driving inflation concerns and pushing bond yields higher, according to the CNBC Investing Club. According to the same source, this commodity rally has sent the 10-year Treasury yield to 4.70%, marking its highest level since January 2025, and caused stocks to pull back as market participants weigh tightening monetary policy expectations.
Federal Reserve Rate Hike Expectations Shift as Treasury Yields Climb
Monetary policy expectations are shifting rapidly as rising energy costs pressure fixed-income markets. According to the CNBC Investing Club, the odds of a Federal Reserve rate hike at the September policy meeting have jumped to roughly 83%, a sharp increase from 53% just one week prior, based on data from the CME FedWatch tool. While current market probabilities still point toward the central bank holding rates unchanged at the upcoming Federal Open Market Committee meeting, hawks are gaining ground as 10-year Treasury yields test multi-month highs.
Alphabet Shares Decline on Second-Quarter Free Cash Flow Concerns
Alphabet shares dropped more than 6% on Thursday, putting the stock on pace for its worst trading day of the year, according to the CNBC Investing Club. The sell-off follows negative free cash flow in the second quarter and an increased full-year capital expenditure outlook. According to the CNBC Investing Club, these figures have amplified market worries that hyperscalers are failing to generate an adequate return on invested capital to justify the ongoing artificial intelligence buildout, despite management teams defending their spending plans.
Eli Lilly Advances Retatrutide Regulatory Pathway Through Biologics License Application
Eli Lilly announced positive results from two late-stage trials evaluating retatrutide, its next-generation obesity treatment that delivers deeper weight loss than existing injectables like Wegovy and Zepbound, according to the CNBC Investing Club. While some market watchers expected an Food and Drug Administration filing before the end of the year, Eli Lilly plans to submit the drug in the first quarter of 2027. According to the CNBC Investing Club, the company is utilizing a Biologics License Application rather than a traditional New Drug Application. This regulatory path, made possible by an October U.S. district court decision, exempts the drug from Medicare price negotiations under the Inflation Reduction Act and offers stronger commercial protections over its lifecycle.
Did You Know?
Retatrutide is often referred to as “triple G” because it targets three distinct hormones involved in appetite regulation that all start with the letter “G,” setting it apart from dual-action and single-action therapies currently on the market.
Upcoming Earnings and Economic Data Calendar
Wall Street is bracing for a heavy slate of corporate earnings and economic releases. According to the CNBC Investing Club, Club name Intel is scheduled to report its quarterly earnings after the closing bell, with investors watching for robust data center server CPU sales and foundry adoption. Before Friday’s opening bell, American Express, Verizon, Charter Communications, SLB, and HCA Healthcare will report results. Additionally, S&P Global will release its July manufacturing and services PMI data alongside June new home sales figures on Friday morning.
Frequently Asked Questions
Why are bond yields rising alongside oil prices?
According to the CNBC Investing Club, surging oil prices—with WTI above $90 and Brent topping $100 per barrel—are fueling broader inflation concerns, which in turn push bond prices lower and drive up yields like the 10-year Treasury.
What is the difference between a BLA and an NDA for drug approval?
According to the CNBC Investing Club, a Biologics License Application is typically used for large, complex molecules derived from living cells and offers stronger commercial protections, including exemption from Medicare price negotiations under the Inflation Reduction Act, compared to a traditional New Drug Application.
How are markets pricing the next Federal Reserve rate decision?
According to data from the CME FedWatch tool cited by the CNBC Investing Club, the market assigns an 83% probability to a Fed rate hike by September.
Stay Ahead of the Market
Get actionable afternoon updates, trade alerts, and deep dives into Wall Street crosscurrents by exploring more of our financial reporting and market analysis.
Keep reading